A Model-Informed Drug Development (MIDD) Approach for a Low Dose of Empagliflozin in Patients with Type 1 Diabetes
Pharmaceutics（2021）
Key words
Bayesian modeling,clinical trial simulations,SGLT2 inhibitor,supportive evidence,type 1 diabetes
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined